How long does it take to develop a new drug: from lab to patient

When we hear about a new drug, we often imagine that it is the result of several years of work in a laboratory. In reality, developing a new medicine is one of the longest and most complex processes in modern medicine.

From the initial idea until the treatment reaches the patients, it can take between 10 and 15 years, and sometimes more. That is why clinical trials play such an important role in the development of new therapies.

How the development of a new drug begins

It all starts with a scientific idea or discovery.

The researchers identified:

• a new biological mechanism;
• molecule with potential therapeutic effect;
• a new approach to treating a particular disease.

Thousands of potential substances can be explored at this stage, but only a small fraction make it to the next stages.

Preclinical studies

Before a drug is tested in humans, it goes through so-called preclinical studies.

These include:

• laboratory tests;
• cellular models;
• studies on biological systems;
• safety and toxicity assessment.

This stage usually takes between 3 and 6 years.

Many potential drugs are dropped right here if they do not show sufficient effectiveness or safety.

Clinical trials - the most important step

After the successful completion of preclinical studies begin clinical trials, evaluating the safety and effectiveness of therapy in humans.

Phase 1

A small number of volunteers participated in the first phase.

The aim is to establish:

• drug safety;
• appropriate dosages;
• the way the body processes it.

Phase 2

The second phase involves patients with the relevant disease.

Here are evaluated:

• the effectiveness of treatment;
• the optimal dose;
• possible side effects.

Phase 3

These are the largest and most important clinical studies.

Hundreds or thousands of patients from different countries can participate.

Phase 3 aims to confirm:

• the effectiveness of therapy;
• long-term safety;
• benefits over existing treatments.

Many of the international studies conducted in Bulgaria are from this phase.

Regulatory approval

Once clinical trials are completed, all data are submitted to regulatory authorities.

In Europe, this includes an estimate of:

European Medicines Agency

Experts analyze:

• the results of the studies;
• safety profile;
• quality of production.

Only if the benefits outweigh the risks does the drug receive a marketing authorisation.

Phase 4 - after approval

Even after a drug reaches the market, monitoring continues.

The so-called Phase 4 tracks:

• long-term safety;
• rare side effects;
• efficiency in real conditions.

This helps to continuously improve medical knowledge.

Why is the process so long

Developing a new drug takes time because patient safety is a top priority.

Each stage is designed to answer important questions:

• Does the treatment work?
• Is it safe?
• In which patients is it most effective?
• What are the potential risks?

This rigorous process ensures that only therapies with proven qualities reach patients.

The role of clinical trials

Without clinical trials, the development of modern medicine would be impossible.

Thanks to them, today we have effective therapies for many diseases, including:

• oncological diseases;
• autoimmune diseases;
• dermatological diseases;
• rare diseases;
• cardiovascular disease.

In addition, participants in clinical trials often gain access to innovative therapies years before they become widely available.

Conclusion

Developing a new drug is a long and complex process that can take more than a decade. From laboratory research to large international clinical trials, every step is aimed at ensuring the safety and effectiveness of future treatments.

This is why clinical trials are among the most important drivers of medical progress and the hope for better therapies in the future.